Heron's Sustol Faces Competition With Narrower Label Than Expected

Heron Therapeutics gained approval of its chemotherapy-induced nausea and vomiting drug Sustol (granisetron), but the company faces stiff competition and postmarketing requirements. Analysts, nonetheless, think the product has a bright future on the US market.